Avzivi Injection, Solution
Product Images NDC 82143-002

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Avzivi (NDC 82143-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bio-thera Solutions, Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100 mg Carton (100 mg Carton)

100 mg Carton (100 mg Carton)
FDA Label Image

400 mg Carton (400 mg Carton)

400 mg Carton (400 mg Carton)
FDA Label Image

Fig-01 (Fig 01)

Fig-01 (Fig 01)
This is a comparison of survival rates between patients who received FOLFOX chemotherapy alone (411 patients) and those who received FOLFOX chemotherapy in combination with bevacizumab (402 patients). The graph shows the duration of survival in months, with 207 months being the lowest survival duration for the FOLFOX alone group and 295 months for the combination group.*
FDA Label Image

Fig-02 (Fig 02)

Fig-02 (Fig 02)
This is a dataset showing the proportion of individuals surviving over different time points in a study comparing the effectiveness of Chemo alone versus Chemo combined with bevacizumab. The numbers represent the count of individuals surviving at specific time intervals. The study involves a randomized treatment approach to evaluate the impact of the combination therapy on survival rates.*
FDA Label Image

Fig-03 (Fig 03)

Fig-03 (Fig 03)
This is a statistical representation showing the proportion of individuals surviving over a certain duration of time, categorized by different treatment groups. The data indicates the number of patients at risk for each group at specific time points, helping in evaluating the effectiveness of the treatments being compared. The study seems to involve two treatment groups, labeled as "PC+bevacizumab" and is assessing survival rates over a period of months.*
FDA Label Image

Fig-04 (Fig 04)

Fig-04 (Fig 04)
This text provides a comparison of the progression-free survival between two groups in a study: one group received placebo plus IFN-alfa (n=322) and the other received bevacizumab plus IFN-alfa (n=327). The progression-free survival is illustrated over a period of 24 months. The data shows the number of patients at risk at different time points in months for each group.*
FDA Label Image

Fig-05 (Fig 05)

Fig-05 (Fig 05)
This text appears to provide information on the proportion of overall survival for two groups receiving different treatments, one with "Chemo alone" and the other with "Chemo + bevacizumab". The data includes the overall survival in months for each group at various time points (6, 12, 18, 24, 30, and 36 months) and the number at risk at these time points for both treatment groups.*
FDA Label Image

Fig-06 (Fig 06)

Fig-06 (Fig 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.